CURX (Curanex Pharmaceuticals) FCF Yield %: -193.97 (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CURX Curanex Pharmaceuticals Inc CURX
12 GF Score
Price $0.21
View Full Analysis

What is Curanex Pharmaceuticals FCF Yield %?

Curanex Pharmaceuticals CURX +7.43% 12 FCF Yield % is -193.97 as of Aug. 01, 2026. GuruFocus rates CURX with a GF Score™ of 12/100. Among 1,408 Biotechnology companies, Curanex Pharmaceuticals ranks worse than 94.67% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Curanex Pharmaceuticals's Trailing 12-Month Free Cash Flow is $-11.29 Mil, and Market Cap is $5.82 Mil. Therefore, Curanex Pharmaceuticals's FCF Yield % for today is -193.97%.

The historical rank and industry rank for Curanex Pharmaceuticals's FCF Yield % or its related term are showing as below:

CURX' s FCF Yield % Range Over the Past 10 Years
Min: -193.97   Med: 0   Max: 0
Current: -193.97


CURX's FCF Yield % is ranked worse than
94.67% of 1408 companies
in the Biotechnology industry
Industry Median: -10.12 vs CURX: -193.97

Curanex Pharmaceuticals's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.


Curanex Pharmaceuticals FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Curanex Pharmaceuticals FCF Yield % Related Terms


Curanex Pharmaceuticals FCF Yield % Historical Data

* Premium members only.

The historical data trend for Curanex Pharmaceuticals's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curanex Pharmaceuticals FCF Yield % Chart

Curanex Pharmaceuticals Annual Data
Trend Dec22 Dec23 Dec24 Dec25
FCF Yield %
0.00 0.00 0.00 -111.89

Curanex Pharmaceuticals Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -180.09 -36.59 -26.34

CURX vs DRMA, NCNA, CELZ: FCF Yield % Comparison

For the Biotechnology subindustry, Curanex Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Curanex Pharmaceuticals FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curanex Pharmaceuticals's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Curanex Pharmaceuticals's FCF Yield % falls into.


CURX
12GF Score
Curanex Pharmaceuticals Inc CURX
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Curanex Pharmaceuticals FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Curanex Pharmaceuticals's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-10.484 / 9.3695346
=-111.89%

Curanex Pharmaceuticals's annualized FCF Yield % for the quarter that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-0.955 * 4 / 14.5030245
=-26.34%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -193.97 mean?
Curanex Pharmaceuticals (CURX) has a FCF Yield % of -193.97 as of Aug. 01, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Curanex Pharmaceuticals and its competitors. According to the industry distribution chart, Curanex Pharmaceuticals ranks #1333 out of 1408 companies in the Biotechnology industry, placing it in the top 94.7%.
Is Curanex Pharmaceuticals' FCF Yield % too high?
Curanex Pharmaceuticals' current FCF Yield % is -193.97. Based on the distribution chart, Curanex Pharmaceuticals ranks #1333 out of 1408 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Curanex Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Curanex Pharmaceuticals' FCF Yield % compare to DRMA and NCNA?
According to the Biotechnology industry distribution chart, Curanex Pharmaceuticals ranks #1333 out of 1408 companies for FCF Yield %. This places Curanex Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Curanex Pharmaceuticals and its competitors. Curanex Pharmaceuticals's current FCF Yield % is -193.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curanex Pharmaceuticals stock overvalued right now?
Curanex Pharmaceuticals (CURX) has a current FCF Yield % of -193.97. The current FCF Yield % is -193.97. Curanex Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Curanex Pharmaceuticals (CURX), the current FCF Yield % is -193.97 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Curanex Pharmaceuticals Business Description

Address 2 Jericho Plaza, B Wing, Suite 101, Jericho, NY, USA, 11753
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.
12GF Score

Get the complete analysis for CURX

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.21
Price